ASLAN, BioGenetics ink deal to commercialize AML therapy in S. Korea
Category: #healthcare  By Mateen Dalal  Date: 2019-03-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

ASLAN, BioGenetics ink deal to commercialize AML therapy in S. Korea
  • ASLAN would grant BioGenetics exclusive rights for commercializing ASLAN003 in South Korea
  • The therapy showed early signs of efficacy and safety in refractory and relapsed AML patients

Clinical-stage oncology-focused biopharmaceutical firm, ASLAN Pharmaceuticals, and BioGenetics Co. Ltd., a leading South Korean healthcare firm, have expanded their strategic partnership by entering into a new commercialization agreement wherein the two parties would partner for commercializing ASLAN003 in all indications in South Korea.

Apparently, ASLAN would grant BioGenetics exclusive rights for commercializing ASLAN003 in South Korea for an upfront payment of US$1 million and then up to US$8 million in development and sales milestones. ASLAN is also eligible for receiving tiered double digit royalties on the net sales from the high-teens to the mid-twenties range.

A press release from ASLAN revealed that the South Korean firm would contribute towards the global R&D costs incurred by ASLAN in the clinical development of ASLAN003 in acute myeloid leukaemia (AML), along with being responsible for obtaining initial and all subsequent regulatory approvals for ASLAN003 in South Korea.

ASLAN003 is purportedly an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) which has the potential of being the first-in-class in AML. Currently, ASLAN is conducting a phase 2A dose optimization study of ASLAN003 in AML and is expecting to conclude the study in the first half of 2019.

At the 60th American Society of Hematology Annual Meeting, ASLAN had seemingly presented a preliminary data from the study in which ASLAN003 showed early signs of efficacy and safety in refractory and relapsed AML patients.

ASLAN003 has allegedly showcased potent inhibition of DHODH, a lack of toxicities related with first generation inhibitors and other novel AML therapies, in previous clinical studies, besides the potential in inducing differentiation in blast cells and applicability in a broad range of AML patients. ASLAN003 has also been awarded orphan drug designation from the U.S. FDA.

For the record, ASLAN had earlier signed an agreement with BioGenetics, in Feb 2019, wherein both parties were to collaborate for commercializing the lead asset of ASLAN, velutinid, in all indications in South Korea.

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

ImmunityBio & NantKwest Begins hAd5-COVID-19’s Phase 1 Clinical Trial
ImmunityBio & NantKwest Begins hAd5-COVID-19’s Phase 1 Clinical Trial
By Mateen Dalal

ImmunityBio, a privately held immunotherapy firm, and NantKwest, a clinical-stage immunotherapy orga...

ICT International brings new rapid antigen COVID-19 testing to Europe
ICT International brings new rapid antigen COVID-19 testing to Europe
By Mateen Dalal

ICT International, a renowned medical testing device manufacturer, is reportedly launching new rapid...

Calibre Scientific Announces Acquisition of Lorne Laboratories
Calibre Scientific Announces Acquisition of Lorne Laboratories
By Mateen Dalal

Calibre Scientific, a varied provider of life science reagents, instruments, tools, and other consum...